Skip to main content
TipRanks
Go Ultimate75% OFF

Clene (84C0) Stock Price & Analysis

1 Followers

84C0 Stock Chart & Stats

€3.04€0.18(6.29%)
At close: 5:30 PM GMT+1
€3.5€4€4.5€5Jun 30Aug 19
Day’s Range
EUR 3.04 - EUR 3.06
52-Week Range
EUR 2.68 - EUR 9.35
Previous Close
EUR 2.86
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 45.93M
Enterprise Value
EUR 72.57M
Total Cash (Recent Filing)
EUR 9.89M
Total Debt (Recent Filing)
EUR 22.60M
Price to Earnings (P/E)
―
Beta
0.75
Next Earnings
Mar 29, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

ALS Regulatory Progress

The ALS NDA submission is a major development milestone that moves CNM-Au8 from clinical development toward potential regulatory review and commercialization. Continued preparation for a confirmatory Phase 3 study also supports the candidate’s strategic importance and development pathway.

Non-Dilutive Development Funding

The NIH subaward provides externally funded support for CNM-Au8 access and development activities, reducing the amount of corporate capital required for this program. Multi-year grant backing also reinforces institutional support for the ALS therapeutic effort.

Insider Capital Support

The insider-led financing supplies near-term liquidity for regulatory dialogue, filings, expanded access, potential commercialization and manufacturing preparation. Participation by company insiders also demonstrates continued financial support for advancing CNM-Au8.

Bears Say

Persistent Unprofitability

The company remains deeply unprofitable, with losses far exceeding its small revenue base and negative TTM gross profit. Such stressed economics make a near-term transition to self-funded operations unlikely and leave future value dependent on clinical and regulatory success.

Ongoing Cash Burn

Cash usage remains substantial even after moderating from earlier years, while free cash flow closely tracks net loss and confirms that losses translate into real funding needs. Continued development therefore requires additional financing or other external capital sources.

Weak Capital Structure

Negative equity and a materially smaller asset base indicate limited balance-sheet flexibility, while sizable debt remains outstanding. This capital structure can constrain investment capacity and increase reliance on future financing as clinical and regulatory spending continues.

Clene News

84C0 FAQ

What was Clene’s price range in the past 12 months?
Clene lowest stock price was €2.68 and its highest was €9.35 in the past 12 months.
What is Clene’s market cap?
Clene’s market cap is €45.93M.
When is Clene’s upcoming earnings report date?
Clene’s next earnings report is estimated for Mar 29, 2027 (not yet confirmed), which is in 128 days.
How were Clene’s earnings last quarter?
Clene released its earnings results on Nov 04, 2026. The company reported €0.243 earnings per share for the quarter, beating the consensus estimate of -€0.412 by €0.655.
Is Clene overvalued?
According to Wall Street analysts Clene’s price is currently Undervalued.
Does Clene pay dividends?
Clene does not currently pay dividends.
What is Clene’s EPS estimate?
Clene’s EPS estimate is -0.43.
How many shares outstanding does Clene have?
Clene has 14,400,175 shares outstanding.
What happened to Clene’s price movement after its last earnings report?
Clene reported an EPS of €0.243 in its last earnings report, beating expectations of -€0.412. Following the earnings report the stock price went up 5.732%.
Which hedge fund is a major shareholder of Clene?
Hedge funds hold Clene shares: the largest hedge-fund position in Clene is 1,663,292,186 shares, and hedge funds decreased their holdings by 68.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology